You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors

  • Authors: Kristen A. Marrone, MD
  • CME / ABIM MOC Released: 2/23/2023
  • Valid for credit through: 2/23/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, surgeons, pathologists, and other clinicians on the multidisciplinary cancer care team.

The goal of this activity is for learners to be better able to understand the role of immunotherapy for the management of early-stage solid tumors and how best to care for patients with these cancer types in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating immunotherapy in early-stage solid tumors
  • Self-assess learning needs related to
    • The care of patients with early-stage solid tumors as part of the multidisciplinary team


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Kristen A. Marrone, MD

    Assistant Professor of Oncology
    Johns Hopkins University School of Medicine
    Baltimore, Maryland


    Participation by Dr Marrone does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Kristen A. Marrone, MD, has the following relevant financial relationships:
    Consultant or advisor for: Daiichi Sankyo, Inc.; Janssen; Mirati; Puma; Regeneron Pharmaceuticals, Inc.
    Research funding from: Bristol Myers Squibb Company; Mirati


  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC


    Davecia R. Cameron, MS, has no relevant financial relationships.

  • Jason Luis Quiñones, PhD

    Associate Medical Writer, Medscape, LLC


    Jason Luis Quiñones, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

SITC Course Director

  • Margaret E. Gatti-Mays, MD, MPH

    Section Chief
    Breast Medical Oncology
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio


    Margaret E. Gatti-Mays, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: GEHealthcare (former)

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and SITC.

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the Society for Immunotherapy of Cancer (SITC). Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors

Authors: Kristen A. Marrone, MDFaculty and Disclosures

CME / ABIM MOC Released: 2/23/2023

Valid for credit through: 2/23/2024



  1. Mittendorf, EA, et al. Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease. ASCO Educ Book. 2022;42:189-203.
  2. Bilusic M. What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy? Exp Rev Anticancer Ther. 2022;22:561-563.
  3. Cascone T, et al. Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2018;78:1719.
  4. Liu J, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382-1399.
  5. Menzies AM, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301-309.
  6. Rozeman EA, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27:256-263.
  7. Ipilimumab [PI]. Approved 2011. Revised May 2022.
  8. Nivolumab [PI]. Approved 2014. Revised March 2022.
  9. Pembrolizumab [PI]. Approved 2014. Revised December 2022.
  10. Durvalumab [PI]. Approved 2017. Revised November 2022.
  11. Atezolizumab [PI]. Approved 2016. Revised December 2022.
  12. Food & Drug Administration (FDA). FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. Accessed February 2, 2023.
  13. O'Brien M, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274-1286.
  14. Food & Drug Administration (FDA). Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval guidance for industry. Published July 2020. Accessed January 18, 2023.
  15. Schmid P, et al; KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  16. Schmid P, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  17. Choueiri TK, et al; KEYNOTE-564 Investigators. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-694.
  18. Kelly RJ, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191-1203.
  19. Marron TU, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:219-229.
  20. Martins F, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563-580.
  21. Kaseb AO, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:208-218.
  22. Forde PM, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  23. Felip E, et al; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  24. Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021;23:1-11.
  25. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer (Version 1.2023). 2022. Accessed January 18, 2023.
  26. Luke JJ, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020;16:4429-4438.
  27. National Comprehensive Cancer Network (NCCN). Melanoma: cutaneous (Version 1.2023). 2022. Accessed January 18, 2023.
  28. National Cancer Institute (NCI). Tumor board review definition. Accessed January 18, 2023.
  29. Läubli H, et al. Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Arch. 2019;474:485-495.
  30. Pankaj Boruah A, et al. Implementation and impact of a novel multidisciplinary immune-related adverse events tumor board for patients receiving immune checkpoint inhibitor therapy. J Clin Oncol. 2021;39e13541.
  31. Katz SJ, et al. Shared decision making for treatment of cancer: challenges and opportunities. J Oncol Pract. 2014;10:206-208.
  32. Viljoen B, et al. Deciding to enroll in a cancer trial: a systematic review of qualitative studies. J Multidiscip Healthc. 2020;13:1257-1281.
  33. National Cancer Institute (NCI). Shared decision making definition. Accessed January 18, 2023.
  34. National Comprehensive Cancer Network (NCCN). Management of immunotherapy-related toxicities (Version 1.2022). 2022. Accessed November 21, 2022.
  35. Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events J Immunother Cancer. 2021;9:1-33.
  36. Sujay Srinivas, et al Immunotherapy in Special and Rare Situations: A Brief Review. J Immunother Precis Oncol. 2021;4:180-184.
  37. Shan Q, et al. Immune Checkpoint Inhibitors in Special Populations. Technol Cancer Res Treat. 2021;1-10.
  38. Johnson DB, et al. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904-1911.
  39. Chmielewska I, et al. Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer-clinical trials experience. Cancers (Basel). 2021;13:1-10.
  40. Roller JF, et al. Exploring the evolving scope of neoadjuvant immunotherapy in NSCLC. Cancers (Basel). 2022;14:1-19.
  41. Tarantino, P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8:1-7.
  42. Lao CD, et al. Current state of adjuvant therapy for melanoma: less is more, or more is better? ASCO Educational Book. 2022;42:738-744.
« Return to: What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors
  • Print